Melanocortin peptides have been shown to produce neuroprotection in experimental ischemic stroke. The aim of the present investigation was to identify the therapeutic treatment window of melanocortins, and to determine whether these neuropeptides chronically protect against damage consequent to brain ischemia. A 10-min period of global cerebral ischemia in gerbils, induced by occluding both common carotid arteries, caused impairment in spatial learning and memory (Morris test: four sessions from 4 to 67 days after the ischemic episode), associated with neuronal death in the hippocampus. Treatment with a nanomolar dose (340 mu g/kg i.p., every 12 h for 11 days) of the melanocortin analog [Nle(4), D-Phe(7)]alpha-metanocyte-stimulating hormone (NDP-alpha-MSH), starting 3-18 h after the ischemic episode, reduced hippocampal damage with improvement in subsequent functional recovery. The protective effect was long-lasting (67 days, at least) with all schedules of NDP-alpha-MSH treatment; however, in the latest treated (18 h) gerbils, some spatial memory deficits were detected. Pharmacological blockade of melanocortin MC4 receptors prevented the protective effects of NDP-alpha-MSH. Our findings indicate that, in conditions of brain ischemia, melanocortins can provide strong and longlasting protection with a broad therapeutic treatment window, and with involvement of melanocortin MC4 receptors, 18 h being the approximately time-limit for stroke late treatment to be effective.

Broad therapeutic treatment window of [Nle(4), D-Phe(7)]alpha-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils / Giuliani, Daniela; Leone, S.; Mioni, C.; Bazzani, Carla; Zaffe, Davide; Botticelli, A. R.; Altavilla, D.; Galantucci, M.; Minutoli, L.; Bitto, A.; Squadrito, F.; Guarini, Salvatore. - In: EUROPEAN JOURNAL OF PHARMACOLOGY. - ISSN 0014-2999. - STAMPA. - 538:(2006), pp. 48-56. [10.1016/j.ejphar.2006.03.038]

Broad therapeutic treatment window of [Nle(4), D-Phe(7)]alpha-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils

GIULIANI, Daniela;BAZZANI, Carla;ZAFFE, Davide;GUARINI, Salvatore
2006-01-01

Abstract

Melanocortin peptides have been shown to produce neuroprotection in experimental ischemic stroke. The aim of the present investigation was to identify the therapeutic treatment window of melanocortins, and to determine whether these neuropeptides chronically protect against damage consequent to brain ischemia. A 10-min period of global cerebral ischemia in gerbils, induced by occluding both common carotid arteries, caused impairment in spatial learning and memory (Morris test: four sessions from 4 to 67 days after the ischemic episode), associated with neuronal death in the hippocampus. Treatment with a nanomolar dose (340 mu g/kg i.p., every 12 h for 11 days) of the melanocortin analog [Nle(4), D-Phe(7)]alpha-metanocyte-stimulating hormone (NDP-alpha-MSH), starting 3-18 h after the ischemic episode, reduced hippocampal damage with improvement in subsequent functional recovery. The protective effect was long-lasting (67 days, at least) with all schedules of NDP-alpha-MSH treatment; however, in the latest treated (18 h) gerbils, some spatial memory deficits were detected. Pharmacological blockade of melanocortin MC4 receptors prevented the protective effects of NDP-alpha-MSH. Our findings indicate that, in conditions of brain ischemia, melanocortins can provide strong and longlasting protection with a broad therapeutic treatment window, and with involvement of melanocortin MC4 receptors, 18 h being the approximately time-limit for stroke late treatment to be effective.
538
48
56
Broad therapeutic treatment window of [Nle(4), D-Phe(7)]alpha-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils / Giuliani, Daniela; Leone, S.; Mioni, C.; Bazzani, Carla; Zaffe, Davide; Botticelli, A. R.; Altavilla, D.; Galantucci, M.; Minutoli, L.; Bitto, A.; Squadrito, F.; Guarini, Salvatore. - In: EUROPEAN JOURNAL OF PHARMACOLOGY. - ISSN 0014-2999. - STAMPA. - 538:(2006), pp. 48-56. [10.1016/j.ejphar.2006.03.038]
Giuliani, Daniela; Leone, S.; Mioni, C.; Bazzani, Carla; Zaffe, Davide; Botticelli, A. R.; Altavilla, D.; Galantucci, M.; Minutoli, L.; Bitto, A.; Squadrito, F.; Guarini, Salvatore
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/303948
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 37
social impact